Published in Cancer on November 01, 1988
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch (2007) 1.05
Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. Eur Radiol (2006) 1.02
Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol (2012) 0.90
Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma. Can Urol Assoc J (2013) 0.89
Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol (2011) 0.88
Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol (2012) 0.84
Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract. Virchows Arch (2006) 0.84
Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol (2011) 0.83
The impact of tumor location and multifocality on prognosis for patients with upper tract urothelial carcinoma: a meta-analysis. Sci Rep (2014) 0.78
Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol (2009) 0.77
Multidetector-row computed tomography (MDCT) in patients with a history of previous urothelial cancer or painless macroscopic haematuria. Eur Radiol (2007) 0.77
Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci (2008) 0.76
Patterns of failure and influence of potential prognostic factors after surgery in transitional cell carcinoma of the upper urinary tract. Int J Clin Oncol (2009) 0.76
The characteristics of recurrent upper tract urothelial carcinoma after radical nephroureterectomy without bladder cuff excision. Yonsei Med J (2015) 0.76
Primary adenocarcinoma of ureter: A rare histopathological variant. Urol Ann (2016) 0.75
Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Des Devel Ther (2014) 0.75
Synchronous RCC and TCC of the Kidney in a Patient With Multiple Recurrent Bladder Tumors. Rev Urol (1999) 0.75
Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma. Clinics (Sao Paulo) (2008) 0.75
Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol (2016) 0.75
Transitional cell carcinoma of the renal pelvis with venous tumor thrombus. Rev Urol (2017) 0.75
Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. Oncotarget (2017) 0.75
'Green revolution' genes encode mutant gibberellin response modulators. Nature (1999) 8.87
The Arabidopsis GAI gene defines a signaling pathway that negatively regulates gibberellin responses. Genes Dev (1997) 7.30
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer (1980) 3.37
Purification of a human prostate specific antigen. Invest Urol (1979) 3.11
Carcinoembryonic antigen in patients with different cancers. JAMA (1972) 2.56
Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin (1993) 2.43
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 2.15
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
American Joint Committee on Cancer prognostic factors consensus conference. Cancer (1999) 2.02
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1988) 1.91
SV40 neutralizing antibodies in sera of US residents without history of polio immunization. Nature (1971) 1.77
Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer (1985) 1.76
Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (1981) 1.73
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate (1999) 1.71
Secondary carcinomas of the kidney. J Urol (1975) 1.59
The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer (1999) 1.58
Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J Clin (1994) 1.58
The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet (1984) 1.54
Two mechanisms for growth inhibition by elevated transport of sugar phosphates in Escherichia coli. J Gen Microbiol (1992) 1.48
The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer (1997) 1.47
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer (1994) 1.46
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer (1991) 1.39
CEA as a monitor of gastrointestinal malignancy. Cancer (1975) 1.33
CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol (1998) 1.29
Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol (1986) 1.29
Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg (1980) 1.27
Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (1993) 1.27
The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer (1996) 1.25
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Prostate antigen: a new potential marker for prostatic cancer. Prostate (1981) 1.18
Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl (1996) 1.17
The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1996) 1.13
Correlations of the orthogonal electrocardiogram and vectorcardiogram with consitutional variables in 518 normal men. Circulation (1967) 1.12
Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate (1999) 1.11
Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res (1981) 1.10
A murine renal cell carcinoma. J Natl Cancer Inst (1973) 1.09
Why is the prostate cancer death rate declining in the United States? Cancer (1998) 1.09
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 1.09
A prostate antigen in sera of prostatic cancer patients. Cancer Res (1980) 1.08
Matrix metalloproteinase homologues from Arabidopsis thaliana. Expression and activity. J Biol Chem (1999) 1.07
Management and survival of carcinoma of the colon: results of a national survey by the American College of Surgeons. Ann Surg (1978) 1.07
Prostate cancer: progress and change. CA Cancer J Clin (1978) 1.06
The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer (1979) 1.05
A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer (1997) 1.05
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate (1997) 1.05
Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin (1993) 1.05
Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol (1998) 1.04
Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res (1980) 1.04
Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology (2000) 1.04
The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer (1996) 1.04
The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol (1982) 1.04
American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin (1997) 1.04
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
Method for identifying prostate cells in semen using flow cytometry. Prostate (1998) 1.04
Chemotherapy of bladder carcinoma with cyclophosphamide and adriamycin. J Urol (1975) 1.03
Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer (1980) 1.03
Immunochemical detection of serum prostatic acid phosphatase. Methodology and clinical evaluation. Invest Urol (1978) 1.03
Fibrin degradation products in renal parenchymal disease states and renal transplant patients. Transplantation (1972) 1.02
Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol (1994) 1.02
An assessment of the current use of human interferons in therapy of urological cancers. J Urol (1989) 1.01
Primary liver tumors and oral contraceptives. Results of a survey. JAMA (1977) 1.01
Search for BK and SV40 virus reactivation in renal transplant recipients. Transplantation (1974) 1.01
Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res (2000) 1.00
American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997. Cancer (1997) 1.00
Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst (1981) 1.00
Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies. J Surg Oncol (1989) 1.00
Revision in American Cancer Society recommendations for the early detection of colorectal cancer. CA Cancer J Clin (1992) 1.00
Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate (1998) 1.00
Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project. J Urol (1994) 1.00
Hormonal therapy in advanced renal cell carcinoma. Cancer (1971) 0.98
Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg (1995) 0.98
Two new, direct, and specific methods of acid phosphatase determination. National field trial. Urology (1979) 0.98
The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging. Cancer (1997) 0.97
Management and survival of female patients with "minimal" breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons. Cancer (1981) 0.97
Brain metastasis from prostatic carcinoma. Cancer (1976) 0.97
Chemotherapy of advanced, hormonally resistant prostatic carcinoma. Oncology (1980) 0.96
Prognostic factors in patients with advanced stage prostate cancer. Cancer Res (1985) 0.96
Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst (1986) 0.96
Secondary involvement of the bladder in malignant lymphoma. J Urol (1977) 0.95
Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg (1974) 0.95
Trends in diagnosis and management of breast cancer in the U.S.: from the surveys of the American College of Surgeons. Cancer (1981) 0.95
Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J Clin (1999) 0.95
Carcinoembryonic antigen. Current clinical status. N Y State J Med (1974) 0.94
The National Cancer Data Base report on patterns of hospital reporting. Cancer (1996) 0.94
Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin. Cancer Chemother Rep (1975) 0.94
Lung metastases in prostatic carcinoma. Clinical significance. Urology (1974) 0.94
The PHYC gene of Arabidopsis. Absence of the third intron found in PHYA and PHYB. Plant Physiol (1994) 0.94
Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma. Cancer (1969) 0.94
Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst (1982) 0.93
The growth and maturation of the National Cancer Data Base. Cancer (1997) 0.93
Molecular characterization of CXCR-4: a potential brain tumor-associated gene. J Surg Oncol (1998) 0.92
Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol (2000) 0.92
Estrogen receptor protein of pancreas. Steroids (1973) 0.92
Pituitary ablation and disseminated prostatic carcinoma. JAMA (1973) 0.92
Current results from therapy of testicular tumors. Cancer (1969) 0.92